Day 2 of ASGCT 2026: VIVEbiotech Strengthens Its Presence in Boston
The company continues its activity at the congress, fostering scientific exchange and networking with the global gene and cell therapy community
VIVEbiotech continues its participation in the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, taking place in Boston, further reinforcing its presence at one of the leading international events in the field.
Following a highly productive first day, the second day of the congress is marked by ongoing scientific engagement and the strengthening of relationships with the global gene and cell therapy community. The VIVEbiotech team remains available at Booth 1619, where it is sharing expertise and exploring new collaboration opportunities with partners and industry professionals.
The team attending the event includes Natalia Elizalde, PhD (Chief Business Development Officer), Marie Fertin (Chief Custom Solution & Process Development Officer), and Víctor Polo (Business Development Manager), who are holding strategic meetings throughout the congress.
As part of the scientific program, VIVEbiotech participated in two key sessions on the yesterday. The first was a company presentation titled “Shaping the Future of Lentiviral Vector Manufacturing: Versatile Platforms for Ex Vivo and In Vivo Applications,” and the second was, “A Collaborative Approach to Enabling Efficient LV Manufacturing for Ex Vivo and In Vivo Gene Therapies” .
VIVEbiotech would like to thank all attendees who participated in the sessions, as well as those who engaged in valuable discussions.
The company would especially like to extend its sincere gratitude to Sartorius | Advanced Therapy Solutions and Sartorius | Bioprocess Solutions for their invaluable collaboration and support.
Throughout the remaining days of the congress, the team will continue to be available at the booth and via the official event app (EventPilot) to further engage with the community.